Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM76UJY)

• Drug Name: E[c(RGDyK)]2 Drug Info
• Synonyms: E[c(RGDyK)]2; CHEMBL414385

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44388431
  TTD Drug ID: DM76UJY

Molecule-Related Drug Atlas

Drug(s) Targeting ITGB3 messenger RNA (ITGB3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEMILOFIBAN	DMBRYT8	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 3	[2]
DMP-802	DMDK6HP	N. A.	N. A.	Discontinued in Phase 1	[3]
SC-47643	DMIE039	N. A.	N. A.	Terminated	[4]
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[5]
L-709780	DMB3ZTI	N. A.	N. A.	Terminated	[6]
Ro-43-8857	DM4VY8S	N. A.	N. A.	Terminated	[3]
SKF-107260	DMM8F0V	N. A.	N. A.	Terminated	[7]
L-738167	DMO69X8	N. A.	N. A.	Terminated	[3]
DMP-757	DMGNUXC	N. A.	N. A.	Terminated	[8]
Ro-43-5054	DMPNHF0	N. A.	N. A.	Terminated	[3]

Drug(s) Targeting Integrin alpha-V (ITGAV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abituzumab	DMTCXSG	Colorectal cancer	2B91.Z	Phase 2	[9]
IMGN-388	DMSYB83	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
SB-223245	DM3JQCF	N. A.	N. A.	Terminated	[5]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[11]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[12]
C(RGDfF)	DMMBESU	Discovery agent	N.A.	Investigative	[13]
Ac-Asp-Arg-Leu-Asp-Ser-OH	DMYHADT	Discovery agent	N.A.	Investigative	[14]
C[-Arg-Gly-Asp-Acpca21-]	DMXCUDV	Discovery agent	N.A.	Investigative	[15]
C-[-Arg-Gly-Asp-Acpca32-]	DMVM7B2	Discovery agent	N.A.	Investigative	[15]
Cyclo-[-Arg-Gly-Asp-Amp22-]	DMBELJK	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-V (ITGAV)	TTT1R2L	ITAV_HUMAN	Inhibitor	[1]
ITGB3 messenger RNA (ITGB3 mRNA)	TTJA1ZO	ITB3_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106.
• [2] Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
• [3] Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
• [4] Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
• [5] Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
• [6] Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
• [7] Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
• [8] Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
• [9] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
• [10] Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
• [11] Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
• [12] 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41.
• [13] Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17.
• [14] Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90.
• [15] Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87.
• [16] Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82.